La cadena de opciones muestra datos clave de las opciones de acciones de Uniti Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Uniti Group..

Uniti Group (NASDAQ:UNIT) Bolsa, Cadena de Opciones

Uniti Group

Uniti is a REIT with about 140,000 route miles of fiber in the us, primarily in the Southeast. It has agreed to merge with Windstream, which will result in Uniti giving up its REIT status and adding a consumer telecom business line. Uniti's business currently consists exclusively of fiber leasing to enterprises. Windstream currently leases the Uniti network and makes up the bulk of Uniti's revenue and profits. The combined firm will own 217,000 route miles of fiber and pass 4.3 million households and 150,000 commercial buildings, mostly in less populated markets in the Southeast. The firm will continue to offer fiber access to enterprises, as Uniti currently does, but residential telecom services will become its largest revenue stream.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CLPR

UNIT

Descubre las últimas calificaciones de analistas para tres acciones inmobiliarias con altos dividendos y perspectivas mixtas.

3 acciones inmobiliarias con alto dividendo y análisis recientes

Uniti Group Inc

UNITE Group PLC

UNITED BULLION EXCH INC by United Bullion Exchange, Inc.

UNITED CORPS LTD by United Corporations Limited

UNITED E&P INC by United E & P, Inc.

UNITED Inc

UNITED PALM OIL INDST PCL by United Palm Oil Industry Public Co Ltd

UNITED WORLD HLDG GRP LTD by United World Holding Group Ltd.

Unit Corp

United Airlines Holdings, Inc. - Common Stock

United Airlines Holdings Inc

UNITED AMERICAN CORP by United American Corp.

United American Corp

UNITED AMER HEALTHCARE CP by United American Healthcare Corp.

United American Healthcare Corp

UNITED AMERICAN PETR by United American Petroleum Corp.

United American Petroleum Corp

United Arrows Ltd

UNITED ARROWS UNSP/ADR by United Arrows Ltd.

United Bancorp Inc

UNITED BNCRP OF AL INC A by United Bancorporation of Alabama, Inc.

United Bancorp Of Alabama Inc

UNITED BNCSHS CLMBUS GRVE by United Bancshares, Inc.

United Bancshares Inc

UNITED BANK LTD GDR 144A by United Bank Ltd.

United Bank Ltd

United Bankshares Inc

Compania Cervecerias Unidas, S.A. Common Stock

United Breweries Co Inc

United Communications Partners Inc

United Community Banks, Inc. Depositary Shares, each representing 1/1000th interest in a share of Series I Non-Cumulative Preferred Stock

United Community Banks Inc

United Community Banks, Inc. Common Stock

UNITED CONSORTIUM LTD by United Consortium Ltd.

United Consortium Ltd

UNITED ENERGY CRP NEV by United Energy Corp.

United Energy Corp

UNITED ENERGY GRP LTD ORD by United Energy Group, Ltd.

United Energy Group Ltd

United Ethanol LLC

United Fire Group Inc

United Hampshire US REIT

UNITED HEALTH PRODUTS INC by United Health Products, Inc.

United Health Products Inc

United Homes Group Inc

United Homes Group, Inc - Class A Common Stock

UNITED INTERNET UNSP/ADR by United Internet AG

United Internet AG

UNITED INTERNET AG&CO REG by United Internet AG

UNITED LABS INTL HLDG ORD by United Laboratories International Holdings Ltd.

United Laboratories International Holdings Ltd

UNITED LITHIUM CORP by United Lithium Corp.

United Lithium Corp

United Malt Group Ltd Ordinary Shares

United Maritime Corporation - Common Stock

United Maritime Corp

United Microelectronics Corporation (NEW) Common Stock

United Microelectronics Corp

UNITED NATL BK CAIRO GA by United National Bank (Cairo, GA)

United National Bank

United Natural Foods Inc

UNITED OVRSEAS BK S/ADR by United Overseas Bank Ltd.

United Overseas Bank Ltd

UNITED OVERSEAS BANK ORD by United Overseas Bank Ltd.

United Parcel Service Inc

United Parks & Resorts Inc

UNITED PLANT BERHAD ORD by United Plantations Berhad

United Plantation Bhd

United Rail Inc

United Rentals Inc

UNITED RES HLDGS GRP INC by United Resource Holdings Group, Inc.

United Resources Holdings Group Inc

UNITED ROYALE HLDGS CORP by United Royale Holdings Corp.

United Royale Holdings Corp

United Security Bancshares - Common Stock

United Security Bancshares

United States 12 Month Natural Gas Fund

United States 12 Month Oil

United States Antimony Corporation Common Stock

United States Antimony Corp

United States Basketball League Inc

United States Brent Oil Fund, LP ETV

United States Cellular Corporation Common Stock

United States Cellular Corp

United States Cellular Corporation 5.500% Senior Notes due 2070

United States Cellular Corporation 6.250% Senior Notes due 2069

United States Commodity Index Fund ETV

United States Copper Index Fund ETV

United States Gasoline Fund LP

United States Lime & Minerals, Inc. - Common Stock

United States Lime & Minerals Inc

United States Natural Gas Fund LP

United States Oil Fund

United States Steel Corporation Common Stock

United States Steel Corp

UNITED SUPER MKTS HLDGS by UNITED SUPER MKTS HLDGS INC.

United Super Markets Holdings Inc

UNITED TENNESSEE BNKSHS by United Tennessee Bankshares, Inc.

United Tennessee Bankshares Inc

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

UNITED URBAN INVT CORP by United Urban Investment Corp.

United Urban Investment Corp

UNITED UTIL GRP S/ADR PLC by United Utilities Group PLC

United Utilities Group PLC

UNITED UTILITIES GRP ORD by United Utilities Group PLC

United-Guardian Inc

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

Unitika Ltd

Unitil Corp

Unitronix Corp

Unity Bancorp Inc

Unity Biotechnology Inc

Unity Software Inc

Unity Wealth Partners Dynamic Capital Appreciation & Options ETF

AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) has outperformed the market over the past 15 years by 4.09% on an annualized basis producing an average annual return of 15.21%. Currently, AerCap Holdings has a market capitalization of $19.64 billion. 
Buying $1000 In AER: If an investor had bought $1000 of AER stock 15 years ago, it would be worth $8,287.54 today based on a price of $108.32 for AER at the time of writing.
<h3>AerCap Holdings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746456312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Morgan Stanley analyst Carlos De Alba maintains United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) with a Equal-Weight and raises the price target from $35 to $38.

Morgan Stanley Maintains Equal-Weight on United States Steel, Raises Price Target to $38

WIIM

TSLA

Tesla shares are trading lower after industry data showed a drop in new car sales in Spain, which could add to concerns over European performance.

Keybanc analyst Justin Patterson maintains Nerdwallet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) with a Overweight and lowers the price target from $18 to $14.

NRDS

Keybanc Maintains Overweight on Nerdwallet, Lowers Price Target to $14

Eaton Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) reported better-than-expected first-<a href="https://www.benzinga.com/quote/ETN/earnings">quarter 2025 results on Friday</a>.
Revenue rose 7% year-over-year (Y/Y) to $6.38 billion, beating the consensus of $6.26 billion. Organic sales growth grew 9% Y/Y. Adjusted EPS rose 13% Y/Y to $2.72, beating the consensus of $2.71.
Paulo Ruiz, Eaton president and chief operating officer, said, "Demand in our end markets continues to drive strong organic growth. As we look ahead, we're confident, even amid broader macroeconomic volatility, we're prepared to meet that demand with a proven strategy to invest in our businesses, drive operational excellence and continue our path of growth."
For 2025, Eaton reiterated adjusted EPS of $11.80 – $12.20 vs. $11.97 consensus estimate. The company revised its organic growth outlook to 7.5%-9.5% from 7% – 9% in the prior year quarter.
For the second quarter, the company expects organic growth of 6%-8% and adjusted EPS of $2.85-$2.95, compared to the street view of $2.98.
Eaton shares gained 0.4% to trade at $299.95 on Monday.
These analysts made changes to their price targets on Eaton following earnings announcement.
<ul>
<li>Wells Fargo analyst Joseph O&#8217;Dea maintained Eaton with an Equal-Weight rating and raised the price target from $270 to $310.</li>
<li>Keybanc analyst Jefferson Harralson maintained the stock with an Overweight rating and raised the price target from $325 to $355.</li>
</ul>
Considering buying ETN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05104227/image-2-18-1024x578.png" alt="" class="wp-image-901619" style="width:599px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05104227/image-2-18-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05104227/image-2-18-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05104227/image-2-18-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05104227/image-2-18.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eaton Analysts Increase Their Forecasts After Better-Than-Expected Q1 Results

JP Morgan analyst James Kirby maintains Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with a Overweight and lowers the price target from $23 to $20.

SNCY

JP Morgan Maintains Overweight on Sun Country Airlines, Lowers Price Target to $20

Morgan Stanley analyst Vincent Andrews maintains Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) with a Equal-Weight and lowers the price target from $12 to $8.

TROX

Morgan Stanley Maintains Equal-Weight on Tronox Holdings, Lowers Price Target to $8

Cuprina Holdings (Cayman) Limited (NASDAQ:<a href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) ("Cuprina" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it had, on April 6, 2025, completed construction of, and obtained ISO 13485 certification and a dealer license for, an operational in-vitro fertilization ("IVF") media production facility in Singapore.
The ISO 13485 certification, which validates that Cuprina's quality management system at the facility meets internationally agreed standards for medical device manufacturing, was issued by United Kingdom Accreditation Service ("UKAS"), a part of the International Accreditation Forum ("IAF"). The dealer license, which confers legal authorization to businesses operating in specific activities including manufacturing, importing, or wholesaling medical devices, was issued by the Singapore Health Sciences Authority (HSA).
Cuprina will collaborate with Ferti-Craft to prepare and submit the required regulatory dossiers for registration with Singapore Health Sciences Authority ("HSA"). The goal is to obtain approval for 14 IVF media product SKUs. The project aims to secure HSA approval for commercial sale before the fourth quarter of 2026.
 &nbsp;

CUPR

Cuprina Holdings Obtains ISO 13485 Certification And Dealer License For Operational IVF Media Production Facility In Singapore

Morgan Stanley analyst John Glass maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Underweight and lowers the price target from $14 to $13.

Morgan Stanley Maintains Underweight on Wendy's, Lowers Price Target to $13

Keybanc analyst Sangita Jain maintains MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight and raises the price target from $140 to $163.

Keybanc Maintains Overweight on MasTec, Raises Price Target to $163

Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $119.87 million.</a>
Auvelity (oral antidepressant) net product sales for the quarter were $96.2 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190347/axsome-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">up 80% year over year</a>.
Approximately 167,000 prescriptions were written for Auvelity in Q1 of 2025. This represents an increase of 76% compared to the same period in 2024 and an increase of 5% compared to the fourth quarter of 2024.
Sunosi, a sleep disorder medicine, generated net product revenues of $25.2 million, up 17%.
Approximately 46,000 prescriptions were written for Sunosi in the U.S., representing an increase of 12% compared to the same period in 2024, but a decrease of 5% compared to the fourth quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44587826/axsomes-solriamfetol-fails-primary-goal-in-depression-study-but-shows-improvements-in-associated-sleep-disorder" rel="noreferrer noopener">Axsome&#8217;s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder</a>
The company reported an adjusted net loss of 68 cents.
Net loss for the first quarter of 2025 was $59.4 million, or $1.22 per share. Compare that to a net loss of $68.4 million, or $1.44 per share, for the comparable period in 2024.
The net loss in the first quarter of 2025 includes $26.2 million in non-cash charges, primarily $23.3 million in stock-based compensation expenses.
FDA Approval: The FDA approved Axsome Therapeutics&#8217; Symbravo (meloxicam and rizatriptan). This treatment is for the acute treatment of migraine with or <a href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" target="_blank" rel="noreferrer noopener">without aura in adults</a>.
The company expects SYMBRAVO to be commercially available in the U.S. in approximately four months (June 2025).
Development Pipeline: 
AXS-05 (dextromethorphan-bupropion)
<ul>
<li>Alzheimer&#8217;s Disease Agitation: In March, Axsome received formal pre-NDA meeting minutes from the FDA for AXS-05 in AD agitation, supporting a supplemental NDA (sNDA) submission. The company is on track to submit the sNDA in the third quarter of 2025. </li>
<li>Smoking Cessation:&nbsp;Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025.</li>
</ul>
<ul>
<li>Solriamfetol (dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist): In March, Axsome announced topline results from the FOCUS Phase 3 trial evaluating the efficacy and safety of solriamfetol in Attention Deficit Hyperactivity Disorder (ADHD) in adults. The company plans to initiate a Phase 3 trial of solriamfetol in ADHD in <a href="https://www.benzinga.com/25/03/44475435/axsome-therapeutics-lower-dose-of-attention-deficient-disorder-candidate-hits-primary-goal" target="_blank" rel="noreferrer noopener">pediatric patients in 2025</a>. </li>
<li>SYMBRAVO (MoSEIC meloxicam-rizatriptan): In February 2025, Axsome announced topline results from the EMERGE Phase 3 trial of Symbravo in migraine patients experiencing inadequate response <a href="https://www.benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inadequate-response-to-commonly-used-drugs" target="_blank" rel="noreferrer noopener">to oral CGRP inhibitors</a>. </li>
<li>AXS-12 (reboxetine): Axsome previously announced the completion of its clinical program of AXS-12 in patients with narcolepsy with cataplexy. The company anticipates submitting an NDA to the FDA in the second half of 2025. </li>
<li>AXS-14 (esreboxetine): Axsome has submitted an NDA to the FDA for AXS-14 for fibromyalgia. The company anticipates the FDA&#8217;s decision on acceptance of the filing in the second quarter of 2025. </li>
<li>In April, Axsome announced topline results from the PARADIGM Phase 3 proof-of-concept trial. The company plans to initiate a Phase 3 trial of solriamfetol in Major Depressive Disorder patients with excessive daytime sleepiness in 2025.</li>
</ul>
<h3 class="wp-block-heading">What&#8217;s Next</h3>
<ul>
<li>Axsome is conducting the ENGAGE Phase 3 study of solriamfetol in Binge Eating Disorder. The company anticipates topline results in 2026. </li>
<li>Axsome is conducting the SUSTAIN Phase 3 study in adults with Shift Work Disorder. Topline data is anticipated in 2026.</li>
</ul>
Price Action: AXSM stock is up 5.16% at $118 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a></li>
</ul>

Biotech

Guidance

Health Care

Movers

General

AXSM

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

<a href="https://www.globenewswire.com/Tracker?data=GAF6ZXp81OZOwqS1hpqpWOIaixgTA0HIn7h3Cye6FgbKz_FafmILW_uCI1y-9uUEwe6jQFFE3orroF87_s3pkw==">Taboola</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) today announced it has reached a new partnership with Samsung to serve news recommendations on Samsung devices and news channels.
Under this new multi-year relationship, Taboola will power news recommendations on Samsung News, the popular news application found on millions of Samsung mobile devices worldwide, in markets across Europe and India.
Today's news extends on a long-term relationship between Taboola and Samsung and adds even more ways for Samsung device users to connect with content from premium publishers. Taboola continues to bring recommendations from its large publisher network directly into offerings from mobile carriers and device manufacturers, helping publishers to increase reader traffic.

SSNLF

TBLA

Taboola Expands Long-Term Partnership With Samsung In New Multi-Year Deal To Power News Recommendations On Samsung News In Europe And India, Boosting Premium Publisher Reach And User Engagement

Morgan Stanley analyst Craig Hettenbach maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $165 to $175.

Morgan Stanley Maintains Overweight on Tenet Healthcare, Raises Price Target to $175

Keybanc analyst Justin Patterson maintains IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) with a Overweight and lowers the price target from $64 to $49.

Keybanc Maintains Overweight on IAC, Lowers Price Target to $49

Morgan Stanley analyst Patrick Wood maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Overweight and lowers the price target from $191 to $173.

Morgan Stanley Maintains Overweight on Teleflex, Lowers Price Target to $173

JP Morgan analyst Michael Rehaut maintains Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) with a Underweight and lowers the price target from $93 to $60.

JP Morgan Maintains Underweight on Stanley Black & Decker, Lowers Price Target to $60

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and crypto markets are entering the second leg of what macro expert Raoul Pal calls the "banana zone", a steep, liquidity-driven bull phase.
What Happened: Speaking at the Sui Basecamp at the Token2049 conference in Dubai, Pal <a href="https://www.youtube.com/watch?v=vAwMwsFVr7g">remained</a> confident in the uptrend despite volatility, citing Bitcoin's historical bull cycles, such as 2017, which included multiple 27–39% corrections along the way. 
"Corrections are normal," Pal said. "You've just gone through a normal one."
Pal sees parallels between the current cycle and the 2017 Trump-era rally: initial macro fear centered around tariffs, dollar strength, and economic slowdown, followed by explosive upside. 
He points to recent dollar weakness as a major tailwind. "A weak dollar is incredibly bullish for global growth," he explained, as it lowers debt costs for foreign borrowers and boosts exports.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45192498/bitcoins-key-level-is-96500-analyst-warns-but-heres-what-could-trigger-a-breakdown">Bitcoin&#8217;s Key Level Is $96,500, Analyst Warns, But Here&#8217;s What Could Trigger A Breakdown</a>
Why It Matters: Pal's analysis is anchored in his "Everything Code" framework, a macro model that correlates asset prices with global liquidity. 
According to him, Bitcoin tracks global liquidity with around 90% accuracy, while the NASDAQ tracks at 95%.
"Crypto is a supermassive black hole that outperforms and sucks in every other asset," Pal said, noting Bitcoin's 27.5 million percent return since 2012. 
He argues this outperformance is why younger investors are drawn to crypto over traditional markets, especially in periods of rising liquidity.
What's Next: Pal outlines three phases in every bull market: Initial breakout, corrective phase (now complete) and banana zone part two, featuring altcoin outperformance.
With financial conditions improving and the business cycle expected to strengthen, Pal projects Bitcoin could climb to $450,000, assuming macro indicators hit forecasted levels.
However, he warns that a 35% correction is still likely within this bull phase, a test of investor discipline that will "shake people out."
"Hold on to your hats. Don't screw this up. Don't lose control of your tokens. Don't use leverage. Don't get your wallets hacked," Pal advised. Despite widespread pessimism in investor surveys, he believes the uptrend will extend into early 2026.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45191302/corporations-will-pour-330-billion-into-bitcoin-by-2029-bernstein">Corporations Will Pour $330 Billion Into Bitcoin By 2029: Bernstein</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Could Hit $450,000, Raoul Pal Says: 'Don't Screw This Up'

Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>) reported in-line loss for the first quarter, after the <a href="https://www.benzinga.com/quote/HUN/earnings">closing bell on Thursday</a>.
The company posted a quarterly loss of 11 cents per share, which met the analyst consensus estimate. The company reported quarterly sales of $1.41 billion which missed the analyst consensus estimate of $1.49 billion.
Peter R. Huntsman, Chairman, President, and CEO, said, &#8220;Since our last earnings call, short term business conditions continue to change markedly. Low visibility and customer uncertainty regarding demand trends over the coming months are pressuring order patterns in many of our key markets, including construction, transportation, and other industrial related markets. The cautious customer order patterns are muting the seasonal volume improvement our markets typically experience during the second quarter. While we are hopeful that demand conditions improve, we are not waiting for that to happen and remain aggressive on costs which include announced workforce reductions as well as asset optimization in both Europe and North America. We are on-track to complete our review of strategic options for our European maleic anhydride business by this summer, which we will communicate once completed. Protecting the balance sheet remains a priority in addition to focusing on cash generation as we navigate the Company through the current environment.&#8221;
Huntsman shares fell 2.8% to trade at $11.77 on Monday.
These analysts made changes to their price targets on Huntsman following earnings announcement.
<ul>
<li>Morgan Stanley analyst Angel Castillo maintained Huntsman with an Equal-Weight rating and lowered the price target from $20 to $13.5.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained the stock with an Overweight rating and lowered the price target from $22 to $20.</li>
</ul>
Considering buying HUN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05103709/image-39-1024x586.png" alt="" class="wp-image-901591" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05103709/image-39-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05103709/image-39-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05103709/image-39-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05103709/image-39.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Huntsman Analysts Cut Their Forecasts Following Q1 Results

Morgan Stanley analyst Terence Flynn maintains Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) with a Equal-Weight and lowers the price target from $15 to $10.

Morgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $10

JP Morgan analyst Anthony Paolone maintains Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Neutral and lowers the price target from $64 to $61.

Comments

Uniti Group

Uniti Group (UNIT) Opciones

Uniti Group (NASDAQ:UNIT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL